| Literature DB >> 32979929 |
Sachiko Kaji1, Nobuyuki Hiruta2, Daisuke Sasai3, Makoto Nagashima4, Rintaro Ohe5, Mitsunori Yamakawa5.
Abstract
BACKGROUND: Cytokeratin-positive interstitial reticulum cells (CIRCs), which are a subgroup of fibroblastic reticular cells (FRCs), are known to be present in the lymph nodes. There have been only a few cases of tumors derived from CIRCs. CASEEntities:
Keywords: Autopsy; Cell morphology; Cytokeratin-positive interstitial reticulum cells; Fibroblastic reticular cells; Transform
Mesh:
Substances:
Year: 2020 PMID: 32979929 PMCID: PMC7519525 DOI: 10.1186/s13000-020-01032-9
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Fig. 1Enhanced computed tomography revealed swelling of the right upper paratracheal lymph node (a, arrow) and right lower paratracheal lymph node (b, arrow). Abnormally high uptake in the right supraclavicular lymph node (c, arrowhead) and right lower paratracheal lymph node (d, arrowheads) was detected by positron emission tomography/computed tomography. The right lower paratracheal lymph node was the main lesion, which was approximately 2.7 cm in size. The right upper paratracheal lymph node and right supraclavicular lymph node were metastatic lesions and showed slight swelling
Fig. 2Histology of the primary cytokeratin-positive interstitial reticulum cell (CIRC) tumor of the biopsied lymph node. a The nodal architecture showed effacement caused by neoplastic proliferation on the left side. Circumferential tumor cell proliferation around follicles was conspicuous on the right side. The tumor margin was vaguely detectable (arrowheads). b Proliferating tumor cells around the germinal center (GC) were large in size and round or polygonal. Most of them had round vesicular nuclei and prominent nucleoli. The abundant cytoplasm was pale to eosinophilic. Tumor cells were admixed with many small lymphocytes, plasma cells and eosinophils. : high-magnification view of the tumor cells
Immunophenotypes of CIRC tumor and small cell carcinoma of this case
| Antibody | Immunophenotype | ||
|---|---|---|---|
| CIRC tumor | Small cell carcinoma | ||
| Primary tumor | Relapsed tumor | ||
| CK7 | + | – | – |
| CK8 | + | + | ± |
| CK18 | + | + | ±(weakly) |
| CAM5.2 | + | + | ± |
| AE1/AE3 | + | + | ± |
| EMA | + | + | + |
| 34βE12 | – | – | – |
| PSA | – | – | – |
| NKX3.1 | – | – | – |
| P504S | – | – | – |
| pCEA | – | – | – |
| CK5/6 | – | – | – |
| CK20 | – | – | – |
| TTF-1 | – | – | ±(weakly) |
| Napsin A | – | – | – |
| p63 | – | – | – |
| p40 | – | – | – |
| NSE | – | – | + |
| Chromogranin A | – | – | ± |
| Synaptophysin | – | – | + |
| CD56 | – | – | + |
| CD3 | – | – | – |
| CD4 | – | – | – |
| CD5 | – | – | – |
| CD8 | – | – | – |
| CD20 | – | – | – |
| CD30 (Ki-1) | – | – | – |
| CD45 (LCA) | – | – | – |
| CD45RO (UCHL-1) | – | – | – |
| CD79a | – | – | – |
| PAX5 | – | – | – |
| EBER-1* | – | – | – |
| Tenascin-C | – | – | – |
| Prolyl 3-hydroxylase 1 | – | – | – |
| l-caldesmon | + | + | – |
| Prolyl 4-hydroxylase 1 | + | + | – |
| Lysyl hydroxylase 3 | + | + | – |
| Transglutaminase II | + | + | – |
| α-SMA | – | – | – |
| CD23 | – | – | – |
| D2–40 | – | – | – |
| Clusterin | – | – | – |
| CNA.42 | – | – | – |
| NGFR, low affinity | – | – | – |
| CD21 | – | – | – |
| CD35 | – | – | – |
| CD1a | – | – | – |
| CD11c | – | – | – |
| Langerin | – | – | – |
| DC-SIGN | – | – | – |
| DC-LAMP | – | – | – |
| CD83 | – | – | – |
| DEC205 | – | – | – |
| S-100 | – | – | – |
| CD68 | – | – | – |
| Fascin | + | + | – |
| Factor XIIIa | – | – | – |
| Melan A | – | – | – |
| HMB45 | – | – | – |
| Desmin | – | – | – |
| Vimentin | + | + | – |
| CD34 | – | – | – |
| CD117 | – | – | – |
| ALK | – | – | – |
| EGFR | < 10% | 20% | – |
| p53 | 95% | 80% | – |
| Ki-67 (hot spot) | > 75% | 15% | < 50% |
– negative, ± partially positive, + diffusely positive, PSA Prostate-specific antigen, NGFR Nerve growth factor receptor, FRC Fibroblastic reticular cell, FDC Follicular dendritic cell, EBER-1 (in situ hybridization) Epstein-Barr virus-encoded small RNA-1, ALK Anaplastic lymphoma kinase, EGFR Epidermal growth factor receptor
Fig. 3Immunohistochemical staining of primary cytokeratin-positive interstitial reticulum cell (CIRC) tumors, relapsed CIRC tumors and small cell lung carcinoma using CAM5.2, AE1/AE3, TTF-1, chromogranin A, synaptophysin, CD56, l-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II antibodies. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were positive for CAM5.2 and AE1/AE3 and negative for TTF-1. Tumor cells of small cell lung carcinoma were focally positive for CAM5.2 and AE1/AE3 and weakly positive for TTF-1. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were negative for chromogranin A, synaptophysin and CD56. Tumor cells of small cell lung carcinoma were focally positive for chromogranin A and strongly positive for synaptophysin and CD56. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were positive for l-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II. Tumor cells of small cell lung carcinoma were negative for l-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II
Fig. 4Electron microscopy analysis of primary cytokeratin-positive interstitial reticulum cell (CIRC) tumor cells. A few interdigitating cell processes were observed (arrow). Some tumor cells had desmosome-like junctions (arrowhead). Of note, the tumor cells had no endocrine granules. Original magnification, × 20,000
Fig. 5Relapsed cytokeratin-positive interstitial reticulum cell (CIRC) tumor and small cell carcinoma at autopsy. a Macroscopic findings of the CIRC tumor invading into the superior vena cava (arrow). b Microscopic findings of the CIRC tumor composed of spindle-shaped cells with a loose flow. Inset: high-magnification view of atypical multinucleated cells. c Small cell carcinoma showing typical histological findings on autopsy. Tumor cells had a high N/C ratio and formed focal molding structures. This finding was completely different from that of CIRC tumors
Clinical data of published CIRC tumors
| Case No. | Diagnosis | Complication (malignancy) | Age | Sex | Nodal / Extranodal | Region | Size | Treatment | Outcome | References |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CIRC tumor | 57 | M | Nodal | Left hilum | NA | A left thoracotomy Radiotherapy; 50 Gy | Alive and well, 9 years | Eur J Cancer 1990; 26: 1121–6 | |
| 2 | CIRC tumor | 44 | M | Nodal | Left hilum | 4 cm | A left thoracotomy | Alive and well, over 3 years | ||
| 3 | CIRC tumor | 61 | M | Nodal | Right hilum | NA | A right thoracotomy Radiotherapy; 50 Gy | Alive and well, 13 months | ||
| 4 | CIRC tumor | 21 | F | Nodal | Mediastinal (superior) | 2.5 cm | CHOP chemotherapy Radiotherapy; 21 Gy VP-16 and CBDCA chemotherapy | Died of disease, 9 months | Am J Surg Pathol 2000; 24: 107–16 | |
| 5 | CIRC tumor | 73 | F | Extranodal | Right proximal forearm | NA | Surgery (excision) | NA | ||
| 6 | CIRC tumor | 62 | M | Nodal | Mediastinal (posterior) | 7.4 cm | Radiotherapy; 65 Gy | NA | ||
| 7 | CIRC tumor | 66 | M | Nodal | Submandibular | 1.5 cm | Surgery (excision) Radiotherapy | Alive and well, 12 months | Histopathology 2003; 43: 491–4 | |
| 8 | FRC tumor (primary) | 70 | F | Nodal | Right submandibular | 3.0 cm | Surgery | Died of disease, 10 months | Histopathology 2003; 43: 583–91 | |
| CIRC tumor (relapse) | Nodal | Local relapse | 9.0 cm | VACOP B chemotherapy Two cycles of CNOP chemotherapy | ||||||
| 9 | CIRC tumor | Rectal adenocarcinoma | 62 | M | Extranodal | Spleen | 0.9 cm | Surgery (low anterior resection, splenectomy) | Alive and well, 2 years | Int J Surg Pathol 2014; 22: 447–50 |
| 10 | CIRC tumor with FDC features | 54 | F | Nodal | Right axillary | NA | Surgery (excision) | Alive and well, 2.5 years | Am J Surg Pathol 2015; 39: 573–80 | |
| 11 | CIRC tumor | Uterine endometrioid carcinoma | 67 | F | Nodal | Pelvic | 3.5 cm | Surgery (hysterectomy, bilateral adnexectomy, pelvic lymphadenectomy) | Alive and well, 9 months | Hum Pathol 2016; 49: 15–21 |
| 12 | Current case (primary) | 75 | M | Nodal | Mediastinal (superior) | 2.7 cm | Surgery (excision) CBDCA and DOC chemotherapy | Died of disease, 29 months | ||
| Current case (relapse) | Small cell lung carcinoma Prostatic latent carcinoma | Extranodal | Right lung apex to the clavicle fossa | 1.5 cm | CDDP and VP-16 chemotherapy Three cycles of NGT chemotherapy Radiotherapy; 30 Gy |
CIRC Cytokeratin-positive interstitial reticulum cell, FRC Fibroblastic reticular cell, FDC Follicular dendritic cell, CHOP Cyclophosphamide, doxorubicin, vincristine, and prednisone, VP-16 Etoposide, CBDCA Carboplatin, VACOP-B Etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin, CNOP Cyclophosphamide, mytoxantrone, vincristin, and prednisone, DOC Docetaxel, CDDP Cisplatin, NGT Nogitecan, NA Not available
Immunohistochemical results of published CIRC tumors
| Author(s) | Primary/Relapse | CAM5.2 (CK8) | CK18 | AE1/AE3 | EMA | Vimentin | Desmin | α-SMA | S-100 | CD21 | CD68 | p53 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gould et al. [ | + | + | + | + | + | – | + | – | ND | ND | ND | |
| Gould et al. [ | + | + | + | + | + | + | + | – | ND | ND | ND | |
| Gould et al. [ | + | + | + | – | + | + | + | – | ND | ND | ND | |
| Chan et al. [ | + | + | + | +/− | + | – | – | – | – | – | ND | |
| Chan et al. [ | + | + | – | – | + | + | + | – | – | – | ND | |
| Chan et al. [ | + | + | + | +/− | + | – | – | – | – | – | ND | |
| Schuerfeld et al. [ | + | + | + | – | + | + | ND | + | – | + | ND | |
| Lucioni et al. [ | *primary | – | ND | – | – | + | – | + | – | – | + | 20% |
| relapse | + | ND | +/− | – | + | – | – | – | – | – | > 60% | |
| Karim et al. [ | ND | ND | + | ND | ND | + | + | – | – | ND | ND | |
| Goto et al. [ | + | ND | + | +/− | ND | – | – | +/− | +/− | – | ND | |
| Bösmüller et al. [ | + | ND | + | – | + | – | – | – | – | + | +/− | |
| Current case | primary | + | + | + | + | + | – | – | – | – | – | 95% |
| relapse | + | + | + | + | + | – | – | – | – | – | 80% |
- negative, +/− often/partially positive, + positive, * primary tumor was diagnosed as fibroblastic reticulum cell tumor; ND Not done